CYP2C19 Cytochrome P450 2C19
CYP2C19 (Cytochrome P450 2C19): 17 variants described, covering health risk, drug response; CPIC pharmacogenomic guidance available.
CYP2C19 and medicines
CYP2C19 is a pharmacogene with CPIC guidance. Star alleles, metaboliser phenotypes and the drugs affected are on the CYP2C19 pharmacogenomics page.
Which CYP2C19 variants does Orviva describe?
- rs12248560 Drug response
- CYP2C19*17 homozygous ultra-rapid metabolizer. Increased clopidogrel activation; may increase bleeding risk.
- rs12769205 Drug response
- CYP2C19*35 homozygous (splicing defect). Loss of CYP2C19 function; typically linked with *2.
- rs17884712 Drug response
- CYP2C19*9 homozygous (R144H). Decreased CYP2C19 function.
- rs4244285 Drug response
- CYP2C19*2 homozygous poor metabolizer. Clopidogrel may be ineffective; consider alternative antiplatelet.
- rs6413438 Drug response
- CYP2C19*10 homozygous (P227L). Decreased CYP2C19 function.
- rs72552267 Drug response
- CYP2C19*6 homozygous (R132Q). Loss of CYP2C19 function; poor metabolizer of clopidogrel, PPIs, and SSRIs.
11 further CYP2C19 variants in the knowledge base have only a brief annotation and are not listed here.
Upload your 23andMe, AncestryDNA or WeGene raw file → · Ask G2: “What do my CYP2C19 variants say about me?”
Genetic associations describe risk across populations, not a diagnosis for any one person. Most variants shift risk modestly and act alongside lifestyle, environment and other genes. Consumer DNA chips do not read every position and can be wrong at any single one. For general education only; talk to a clinician or genetic counsellor before acting on anything here, and never change a prescribed medicine without your prescriber.